Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05476562 · ClinicalTrials.gov registry record
Study Conducted Among Patients With CML
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 3,234
- Enrollment target
NCT05476562 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 3,234 participants.
The verdict
NCT05476562 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 3,234 participants
- Enrollment target
Study Summary
Retrospective, non-interventional observational cohort study conducted among patients with CML.
Interventions
- OTHER Tyrosine Kinase Inhibitors (TKIs)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,234 participants |
| Start Date | 2021-03-08 |
| Est. Completion | 2021-10-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05476562
The ClinicalTrials.gov registry entry for NCT05476562 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3,234 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tyrosine Kinase Inhibitors (TKIs) is the first listed.
NCT05476562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05476562 about?
NCT05476562 is a clinical study titled "Study Conducted Among Patients With CML". Retrospective, non-interventional observational cohort study conducted among patients with CML.
What is the current status of trial NCT05476562?
This trial is currently completed. The enrollment target is 3,234 participants. The study started on 2021-03-08. Estimated completion is 2021-10-15.
What interventions are being tested in trial NCT05476562?
The interventions under investigation include: Tyrosine Kinase Inhibitors (TKIs) (OTHER).
Who is sponsoring clinical trial NCT05476562?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.